Anavex Life Sciences (US:AVXL)2025-11-25 12:30Financial Performance - Cash and cash equivalents were $102.6 million as of September 30, 2025, down from $132.2 million a year earlier, indicating a decrease of approximately 22.3%[12] - The net loss for the fourth quarter was $9.8 million, or $0.11 per share, compared to a net loss of $11.6 million, or $0.14 per share for the same quarter in fiscal 2024, showing an improvement of 15.9%[12] - The company reported a total operating loss of $51.4 million for the year ended September 30, 2025, compared to $52.9 million for the previous year, indicating a slight improvement of 2.8%[18] Expenses - Research and development expenses for the fourth quarter were $7.3 million, a decrease of 37.8% compared to $11.6 million in the same quarter of fiscal 2024[12] - General and administrative expenses for the quarter increased to $3.5 million, up from $2.7 million in the comparable quarter of fiscal 2024, representing a rise of 29.6%[12] - Total operating expenses for the fourth quarter were $10.8 million, down from $14.3 million in the same quarter of fiscal 2024, reflecting a decrease of 24.8%[12] Clinical Development - The company plans to advance ANAVEX®3-71 towards pivotal clinical studies for the treatment of schizophrenia-related disorders[4] - Anavex's clinical pipeline includes updates on regulatory and clinical trials for blarcamesine in early Alzheimer's disease, Parkinson's disease, and Rett syndrome[4] - Anavex intends to request a re-examination of the CHMP opinion regarding the Marketing Authorisation Application for blarcamesine, following a negative trend vote[12] Cash Position - The company has a current cash runway of more than 3 years based on its current cash utilization rate, with a cash balance of over $120 million as of now[12]